264 related articles for article (PubMed ID: 8533159)
1. Cisplatin and DNA repair in cancer chemotherapy.
Zamble DB; Lippard SJ
Trends Biochem Sci; 1995 Oct; 20(10):435-9. PubMed ID: 8533159
[TBL] [Abstract][Full Text] [Related]
2. [Advances of DNA damage repair and Cisplatin resistance mechanisms in lung cancer].
Tang C; Yang H; Zhou X
Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):960-4. PubMed ID: 22152698
[TBL] [Abstract][Full Text] [Related]
3. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
4. Cellular and molecular determinants of cisplatin resistance.
Perez RP
Eur J Cancer; 1998 Sep; 34(10):1535-42. PubMed ID: 9893624
[TBL] [Abstract][Full Text] [Related]
5. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?
Bowden NA
Cancer Lett; 2014 May; 346(2):163-71. PubMed ID: 24462818
[TBL] [Abstract][Full Text] [Related]
6. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
To KK; Tong WS; Fu LW
Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
[TBL] [Abstract][Full Text] [Related]
7. Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment.
Kiss RC; Xia F; Acklin S
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360968
[TBL] [Abstract][Full Text] [Related]
8. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
Wang Z; Xu Z; Zhu G
Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
[TBL] [Abstract][Full Text] [Related]
9. Enhanced excision repair of DNA damage due to cis-diamminedichloroplatinum(II) in resistant cervix carcinoma HeLa cells.
Chao CC
Eur J Pharmacol; 1994 Aug; 268(3):347-55. PubMed ID: 7805758
[TBL] [Abstract][Full Text] [Related]
10. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
11. The role of DNA repair pathways in cisplatin resistant lung cancer.
O'Grady S; Finn SP; Cuffe S; Richard DJ; O'Byrne KJ; Barr MP
Cancer Treat Rev; 2014 Dec; 40(10):1161-70. PubMed ID: 25458603
[TBL] [Abstract][Full Text] [Related]
12. Cross-resistance to cis-diamminedichloroplatinum(II) of a multidrug-resistant lymphoma cell line associated with decreased drug accumulation and enhanced DNA repair.
Chao CC
Eur J Pharmacol; 1996 Jun; 305(1-3):213-22. PubMed ID: 8813556
[TBL] [Abstract][Full Text] [Related]
13. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease.
Huang JC; Zamble DB; Reardon JT; Lippard SJ; Sancar A
Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10394-8. PubMed ID: 7937961
[TBL] [Abstract][Full Text] [Related]
14. Recognition of platinum-induced DNA damage by nuclear proteins: screening for mechanisms.
Marples B; Adomat H; Billings PC; Farrell NP; Koch CJ; Skov KA
Anticancer Drug Des; 1994 Oct; 9(5):389-99. PubMed ID: 7945723
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro.
Dabholkar M; Bradshaw L; Parker RJ; Gill I; Bostick-Bruton F; Muggia FM; Reed E
Environ Health Perspect; 1992 Nov; 98():53-9. PubMed ID: 1486863
[TBL] [Abstract][Full Text] [Related]
16. FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer.
He L; Luo L; Zhu H; Yang H; Zhang Y; Wu H; Sun H; Jiang F; Kathera CS; Liu L; Zhuang Z; Chen H; Pan F; Hu Z; Zhang J; Guo Z
Mol Oncol; 2017 Jun; 11(6):640-654. PubMed ID: 28371273
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin resistance and regulation of DNA repair in cAMP-dependent protein kinase mutants.
Liu B; Cvijic ME; Jetzt A; Chin KV
Cell Growth Differ; 1996 Aug; 7(8):1105-12. PubMed ID: 8853907
[TBL] [Abstract][Full Text] [Related]
18. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
19. The HMG-domain protein Ixr1 blocks excision repair of cisplatin-DNA adducts in yeast.
McA'Nulty MM; Lippard SJ
Mutat Res; 1996 Jan; 362(1):75-86. PubMed ID: 8538651
[TBL] [Abstract][Full Text] [Related]
20. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II).
Eastman A; Schulte N
Biochemistry; 1988 Jun; 27(13):4730-4. PubMed ID: 3167012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
